Day One Biopharmaceuticals, Inc.

DAWNDelisted Apr 23, 2026

Industry: Pharmaceutical Preparations
SEC CIK: 0001845337

SEC filings (opens in a new tab)

Day One Biopharmaceuticals, Inc. was delisted on Apr 23, 2026; its insiders filed their last Form 4 on Apr 27, 2026; 208 institutions reported holding it in 13F filings for Q1 2026, worth $1.85B in total; Soros Fund Management was the only superinvestor holding it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 208; Q1 2026, +28 vs. previous quarter
13F value: $1.85B; Reported value at the end of Q1 2026
Superinvestors holding: 1; At the end of Q1 2026

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $158.2M; +20.6% year over year
Net income, FY2025: -$107.3B; No comparable prior period
Free cash flow, FY2025: -$104.1M; No comparable prior period
Revenue, Q4 FY2025: $53.7M; +83.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $107.3B (67847.2% of revenue).

Short interest

See short data

From FINRA, settlement date Apr 15, 2026.

Short interest: 6.58M; Shares sold short
Change: −657.8K; −9.1% vs. previous
Days to cover: 5.39; At average daily volume

Superinvestors holding DAWN, Q1 2026

Go to the superinvestors tab

1 superinvestor reports holding Day One Biopharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Soros Fund Management

George Soros

0.5%

Day One Biopharmaceuticals, Inc.'s share of the portfolio

Shares: 1,539,100
Value: $33.0M

Latest insider trades

See all insider trades

Open-market purchases and sales by Day One Biopharmaceuticals, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change
Feb 18, 2026 (view filing)	Feb 17	1 day	Bender JeremyCHIEF EXECUTIVE OFFICER	SSale	−15.5K	$11.60	−$179.3K	−7.0%204.6K after
Feb 18, 2026 (view filing)	Feb 17	1 day	Merendino LaurenChief Commercial Officer	SSale	−5.81K	$11.60	−$67.4K	−8.8%60.2K after
Feb 18, 2026 (view filing)	Feb 17	1 day	Dubow AdamGen Counsel & Secretary	SSale	−6.39K	$11.60	−$74.2K	−8.1%72.7K after
Feb 18, 2026 (view filing)	Feb 17	1 day	Vasconcelles MichaelHead of Research and Dev.	SSale	−2.73K	$11.60	−$31.6K	−38.3%4.40K after
Feb 18, 2026 (view filing)	Feb 17	1 day	York Charles N IICOO and CFO	SSale	−6.07K	$11.60	−$70.4K	−1.9%312.0K after
Nov 18, 2025 (view filing)	Nov 17	1 day	Bender JeremyCHIEF EXECUTIVE OFFICER	SSale	−15.9K	$8.91	−$141.6K	−8.2%177.2K after
Nov 18, 2025 (view filing)	Nov 17	1 day	Merendino LaurenChief Commercial Officer	SSale	−3.73K	$8.91	−$33.2K	−6.8%50.8K after
Nov 18, 2025 (view filing)	Nov 17	1 day	Dubow AdamGen Counsel & Secretary	SSale	−4.32K	$8.91	−$38.5K	−6.5%62.6K after
Nov 18, 2025 (view filing)	Nov 17	1 day	York Charles N IICOO and CFO	SSale	−4.06K	$8.91	−$36.2K	−1.4%294.7K after
Aug 19, 2025 (view filing)	Aug 18	1 day	York Charles N IICOO and CFO	SSale	−4.11K	$6.77	−$27.8K	−1.5%278.0K after

Top 10 13F holders, Q1 2026

See all 208 holders

The largest institutional positions in Day One Biopharmaceuticals, Inc. at the end of Q1 2026; share changes are against Q4 2025.

Institutions holding DAWN in Q1 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
BlackRock, Inc.	7,044,487	$151.0M	0.00%	−1,793,087−20.3%	Reduced
Glazer Capital, LLC	4,683,687	$100.4M	2.13%	+4,683,687	New
FIL Ltd	4,131,907	$88.6M	0.07%	+4,131,907	New
Kryger Capital LLC	3,896,485	$83.5M	5.91%	+3,896,485	New
Deerfield Management Company, L.P. (Series C)	3,723,131	$79.8M	0.94%	00.0%	Unchanged
Vanguard Capital Management LLC	3,357,684	$72.0M	0.00%	+3,357,684	New
JPMorgan Chase & Co	3,134,753	$67.1M	0.00%	+3,091,223+7,101.4%	Added
State Street Corp	2,869,876	$61.5M	0.00%	−1,419,690−33.1%	Reduced
Balyasny Asset Management LLC	2,625,235	$56.3M	0.11%	+1,135,311+76.2%	Added
CNH Partners LLC	2,462,154	$52.8M	0.87%	+2,462,154	New

Holders of 5% or more of DAWN

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Day One Biopharmaceuticals, Inc..

Largest holders of DAWN from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
BlackRock, Inc.	13G	5.80%5.85M shares	+1.10 ppfrom 4.70%	Apr 28, 20252 filings	Jul 17, 2025	SEC
Glazer Capital, LLC	13G	5.40%5.62M shares	New	Mar 19, 20261 filing	Mar 19, 2026	SEC